

Percutaneous Pulmonary Valve Implantation (PPVI) with Melody®: First Ever Case Report in South Asia

NN FATEMA^a, MR HOSSAIN^b

Summary:

An eleven years old boy was diagnosed as a case of Tetralogy of Fallot (TOF) with absent left pulmonary artery (LPA) since two years of age. He had history of total corrective surgery in 2007 from India. He developed severe right pulmonary artery

origin stenosis, severe tricuspid and pulmonary valve regurgitation after surgery and redo surgery was performed in 2009. During redo surgery an orthotropic conduit was placed between right ventricular (RV) out flow tract and

Introduction:

Trans-catheter pulmonary valve therapy is an alternative to surgery for children and adult who have a failing surgically placed conduit for congenital heart defect like Tetralogy of Fallot (TOF), Pulmonary Atresia, Transposition of Great Arteries (TGA), Double Outlet Right Ventricles (DORV) etc. Conduits are considered as not functioning when it has become stenotic (RVOT gradient greater more than or equal to 35 mm Hg) or regurgitant (moderate or more severe regurgitation)¹. Percutaneous pulmonary valve implantation (PPVI) is a new treatment option in patients with RVOT conduit dysfunction. Conduit size of the individual must be equal to or greater than 16 mm in diameter to qualify for the procedure. Melody® is a replacement pulmonary heart valve used for above purpose.

The objective of PPVI is to prolong the life span of right ventricle to pulmonary artery conduit thus postponing open heart surgery²⁻⁴.

Early follow up result of the procedure showed significant reduction of RV pressure and RVOT gradient. The most common complication which may be encountered in follow up is stent fracture⁵.

-
- a. Col (Dr.) Nurun Nahar Fatema, Paediatric Cardiologist, Combined Military Hospital Dhaka
b. Major General (Prof) Md. Rabiul Hossain, Consultant Physician, Bangladesh Armed Forces

Address of Correspondence: Col. (Dr.) Nurun Nahar Fatema, CMH Dhaka, Phone-01819239021.

Received: 17 July, 2013

Accepted: 7 February, 2014

pulmonary artery. He developed significant conduit dysfunction in the form of stenosis and regurgitation in 2011 and planned for Melody® trans-catheter pulmonary valve replacement. Finally in 25th December 2012, first ever case of pulmonary valve replacement in South Asia was performed in catheterization laboratory of CMH Dhaka with technical support from a Saudi cardiac team. Patient was discharged three days after the procedure with a fully functioning Melody® valve without any stenosis or regurgitation.

(J Bangladesh Coll Phys Surg 2014; 32: 102-106)

So PPVI has the potential to become the standard procedure in the treatment of dysfunctional conduit. We report the first case of PPVI in South Asia where a Melody® with 20 mm ensemble was used in 11 years old boy successfully.

Case report:

J, an eleven years old boy was diagnosed as Tetralogy of Fallot (TOF) with absent left pulmonary artery at the age of two years. He had his first surgery on 27th July 2007 in Narayana Hridayalaya, Bengalore, India which was a trans-atrial repair.

During his follow up, some residual and new problems were observed in echocardiography, chest x-ray and electrocardiography. Patient was symptomatic also in the form of exertional dyspnoea.

So cardiac catheterization was repeated on 3rd September 2008 and severe right pulmonary artery (RPA) origin stenosis, severe tricuspid regurgitation (TR) and severe pulmonary regurgitation (PR) was noticed.

He was referred again to same centre of India for Redo surgery.

This time an orthotropic conduit (23 mm aortic homograft) was placed between RV out flow tract (RVOT) to pulmonary artery (PA) on 22nd January 2009.

He was doing well in first one year of follow up.

Later he again developed easy fatigability. His echocardiography showed severe conduit stenosis (15th December 2011) of PPG 65 mm Hg with calcified area

of 10 mm, free PR and dilated RA RV , RVOT with RVOT diameter of 18 mm. It is a common complication of conduit placement.

He was planned for PPVI as parents were refusing further surgery. Communication for procurement of valve from Medtronic, USA started.

It took about a year to arrange things to have a launching program in Combined Military Hospital (CMH) Dhaka for the first ever case of PPVI not only in Bangladesh but also in South Asia.

J was taken into cath Lab on 25th December 2012 for the procedure.

Procedure:

Equipment required.

- Short introducer sheath 18F
- Pigtail catheter 7F
- Multi track catheter 7F
- High pressure balloon Neumed 22 mm X 4 cm
- Inflation device
- BIB balloon catheter 22 mm X 4 cm
- Dilator 18F
- CP stent 39 mm and 42 mm
- Melody valve
- Ensemble delivery system (20 mm)

Steps:

Right femoral vein and right femoral artery accessed. Patient was heparinized as per standard protocol. Pressure run was recorded in Aorta, LV, RV and pulmonary artery.

Aortogram was done to assess coronary artery arrangement.

RVOT angiogram was done to assess morphology of RVOT and conduit, and severity of stenosis. Pulmonary angiogram was done to look for severity of regurgitation.

A 14F Mullin sheath was guided over a landerquest wire into PA and dilator was removed. Balloon dilatation of conduit was done with 22 mm high pressure balloon.

A CP stent of 39 mm length was placed inside conduit to cover the calcified area.

Another 42 mm CP stent was again implanted to cover the whole length of conduit and BIB balloon of 20 mm was used for expansion of stent.

The Melody valve was washed in 3 saline baths for 5 minutes each to clear the glutaraldehyde preservative.

The Ensemble of 20 mm was flushed and the balloons were deaired.

The venous access was dilated with dilators upto 22 mm.

The valve was crimped on the balloon catheter of the delivery system carefully to orientate it in the direction of blood flow and finally covered with the outer sheath.

The valve over the ensemble was forwarded over the wire to the site of implantation

The valve was uncovered at the optimum site. Check angiography was performed through side port to confirm the site of implantation. Dilatation of inner balloon was followed by dilatation of outer balloon to deploy valved stent.

The delivery system was pulled out carefully keeping the guide wire in position.

Repeat hemodynamic assessment was performed and angiography was done at pulmonary artery.

No PR or PS was noticed. Haemostasis was achieved by applying a tie with silk. Patient was shifted to cardiac ICU after extubation.

Echocardiography on next morning showed well functioning Melody valve with negligible residual



Fig.-1: Pulmonary artery angiogram showing dysfunctional conduit.



Fig.-2: RVOT landing zone after placing two CP stent.




Fig.-3: Melody® valved stent deployed after inflation of inner and outer balloon.

pulmonary stenosis (PPG 15 mm Hg) and no PR. Patient was discharged after 03 days with an advice to continue Aspirin for 06 months and follow up after 04 weeks.

Discussion:

Congenital cardiac defect involving the right ventricular outflow tract (RVOT) require initial surgical interventions as early as the neonatal period. These defect may include severe pulmonic stenosis, pulmonary Atresia with or without ventricular septal defect,

Tetralogy of Fallot, Transposition of the great arteries and Truncus arteriosus^{6,7,8}.

The surgical correction of above conditions often includes the creation of an artificial right ventricle (RV) to pulmonary artery (PA) connection by RV to PA conduit. After repair, over time, these conduits are prone to develop valve dysfunction leading to pulmonary regurgitation (PR), stenosis (PS), thrombosis, infections and calcifications^{9,10}. Chronic PR after relief of RV out flow tract obstruction can lead to RV¹¹ dilatation, biventricular dysfunction, heart failure symptoms, arrhythmia and sudden death¹¹. There is a very close relationship between the degree of PR and RV volumes which was confirmed by many studies¹¹⁻¹⁵. Tetralogy of Fallot is the most common form of cyanotic congenital heart disease with frequency of 06-08 per 1000 live birth¹⁶. Total surgical repair was available for last 50 years with favorable outcome in most cases. But surgical repair of tetralogy of Fallot (TOF) may results in many anatomic and functional abnormalities. In the majority of patients in follow up period most common problems are pulmonary regurgitation and conduit stenosis. Though RV volume overload due to severe PR tolerated over years, there is now evidence that the compensatory mechanisms of the right ventricular myocardium ultimately fail and that if the load is not eliminated or reduced, the dysfunction might be irreversible¹⁷. As a result early pulmonary valve replacement is recommended in many centers.

Pulmonary valve replacement can be performed electively with little risk and may improve symptoms of right ventricular failure and provide excellent midterm survival in above mentioned group of patient¹⁸.

Our patient was a case of TOF with absent left pulmonary artery who had surgery on two occasions earlier, than pulmonary valve replacement was decided for conduit dysfunction.

Indications for PPVI are¹⁹

- Severe pulmonary regurgitation.
- Residual RVOT obstruction >30 mm Hg.
- Electrocardiographic evidence of QRS prolongation >180 milliseconds.

Candidates for PPVI must also fulfill the anatomic requirements necessary for safe anchoring of the percutaneous valve: So conduit provide such properties

for PPVI. In contrast native or patched out flow after TOF repair tends to be dilated and remain dynamic and therefore do not provide a secure implantation site¹⁹.

In our case we have used Melody valve which was approved by Food and Drug Administration (FDA) in USA in January 2010.

Procedure related risks are stent fracture, embolization of valve, acute coronary compression etc. Coronary compression demands urgent surgical intervention.

Experience of PPVI in two centre over 100 patients showed excellent result regarding reduction of RVOT gradient and PR²⁰.

Outcome of pulmonary valve replacement in 170 patients with chronic PR after relief of ROVT obstruction was also found acceptable in another study¹¹.

Early result from the US clinical trial on Melody transcatheter pulmonary valve also recommends the procedure as safe and effective one²¹.

A multicentre survey was performed by Italian society of pediatric cardiology (SICP) to analyze the data of patients treated by Melody Medtronic valve²². This study result showed that the procedure is safe and successful. Major concerns are related to the occurrence of stent fracture and bacterial endocarditis.

Conclusion:

Percutaneous pulmonary valve implantation (PPVI) is a new treatment option in patient with RVOT conduit regurgitation and stenosis. Early results following PPVI have shown a significant reduction in right ventricular pressure and RVOT gradient. The most common complication of PPVI is stent fracture or PR in the context of endocarditis. We got excellent result in our first case. So PPVI has the potential to become the standard procedure in the treatment of dysfunctional conduit and will be easy to procure if price is considered for the developing countries.

References:

1. wwwp Medtronic.com > news room home > Media kits.
2. Oosterhof T, Hazekamp MG, Mulder BJ. Opportunities in pulmonary valve replacement. *Expert Rev Cardiovasc Ther*. 2009;7(9): 1117-1122.
3. Neyt M, Vinck I, Gewillig M, Van Brabant H. Percutaneous Pulmonary and aortic valve insertion in Belgium: Going for

- conditional reimbursement or waiting of further evidence? *Int J Technol Assess Health Care* 2009;25(3):281-289.
4. Zahn EM, Hellenbrand WE, lock JE, McElhinney DB. Implantation of the melody transcatheter pulmonary valve in patient's valve in patients with a dysfunction right ventricular outflow tract conduit early from the U.S. Clinical trial. *J Am Coll Cardiol*. 2009; 54(18): 1722-1729.
5. Vezmar M, Chaturvedi R, Lee KJ et al. Percutaneous pulmonary valve implantation in the young 2-year follow-up. *JACC Cardiovasc Interv* 2010; 3(4):439-448.
6. Weil Alkashkari, Qi-Ling Cao, Clifford J. Kavinsky, Ziyed M Hijaji. Percutaneous pulmonary valve implantation for RVOT Defect . *Cardiac Interventions today* 2010;10:1-12
7. Bove EL, Byrum CJ, Thomsen FD. The influence of pulmonary insufficiency on ventricular function following repair of tetralogy of Fallot. Evaluation using radionuclide ventriculography. *J Thoracic Cardiovasc Surg* 1983; 85: 691-696.
8. De Ruijter FT, Weenink I, Hitchcock FJ. Right ventricular dysfunction and pulmonary valve replacement after correction of Tetralogy of Fallot. *Ann Thorac Surg* 2002;73:1794-1800
9. Therrien J, Siu SC, McLaughlin PR et al. Pulmonary valve replacement in adults late after repair of tetralogy of Fallot: are we operating too late? *J Am coll cardiol*. 2000;36: 1670-1675.
10. Gera T. Indications and timing of pulmonary valve replacement after tetralogy of Fallot repair. *Semin Thorac Cardiovasc Surg pediatric Surg annu* 2006;11-22.
11. Cheuf Lee, Yaug Min Kim, Chang Ha lee, Jae Gun kwak, Chun Soo Park, Ju Young Song et al. Outcome of pulmonary valve replacement in 170 patients with chronic pulmonary regurgitation after relief of ventricular outflow tract obstruction. *J Am coll cardiol* 2013;60 (11):1005-1024.
12. Geva T., Sandweiss B.M, Gauvreau k., Lock J.W., Powell A.J. Factors associated with impaired clinical status in long-term survivors of tetralogy of Fallot repair evaluated by magnetic resonance imaging. *J Am Coll Cardiol* 2004; 43: 1068-1074.
13. Bouzas B., Kiler P.J., Gatzoulis M.A., Pulmonary regurgitation: not a benign lesion, *Eur Heart J* 2005 26 () 433-439.
14. Cheung E.W., Wong W.H., Cheung Y.F.. Meta-analysis of pulmonary valve replacement after operative repair of tetralogy of Fallot, *Am J Cardiol* 2010 106 () 552-557
15. Geva T., Gauvreau K., Powell A.J., et al. Randomized trial of pulmonary valve replacement with and without right ventricular remodeling surgery, *Circulation* 2010 122 () s201-S208
16. Geva T. indications and timing of pulmonary valve replacement after Tetralogy of Fallot repair. *Semin thorac Cardiovasc Surg pediatric Card Surg annu* 2006;3447:11-22
17. Shachin Khambadkone, Philip Bonhoeffer. Complications of percutaneous pulmonary valve replacement in Complications

- during percutaneous interventions in congenital and structural heart disease. Editors Ziyad M Hijaji, Ted Feldman, John P Cheatham, Horst Sievert. Informa Health care 2009 UK Ltd.
18. Emanuela R. Valsangiacomo Buceched, Hitendu H. Dave, Christian J. Kellenberger, Ali Dodge-khatami, Rene Pretre, Felix Barger and Urs Bauersfeld. Remodelling of the right ventricle after early pulmonary valve replacement in children with repaired Tetralogy of Fallot: Assessment by cardiovascular magnetic resonance. *Eur Heart J* (December 2005) 26 (24) 2721-2727.
 19. D Ruijter FT, Weenink I, Hitchcock FJ et al. Right ventricular dysfunction and pulmonary valve replacement after correction of Tetralogy of Fallot. *Ann Thorac surg* 2002; 73:1794-1800.
 20. Andress Eicken, Peter Ewert, Alfred Hager, Bjoren Peters, Sohrab Fratz, Titus Kuchne et al. Percutaneous pulmonary valve implantation: two centre experience with more than 100 patients. *European Heart Journal* 2011; 32:1260-1265.
 21. Evan M Zahn, William E. Hellenbrand, James E Lock, Dott B. McElhinney. Implantation of the Melody transcatheter pulmonary valve in patients with a dysfunctional right ventricular outflow tract conduit. *J Am Col Cardiol* 2009;54 (18): 1722-1729
 22. Gianfranco Butera, Ornella Milanesi, Isabella Spadoni, Luciane Piazza, Andrea Donti, Christian Ricci et al. Melody transcatheter pulmonary valve implantation, Results from the Registry of the Italian society of pediatric Cardiology. *Cath Cardiovasc Interv* 2013; 81: 310-316.